Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 04/11/2020 Analysegerät und Kartusche

    Rapid coronavirus test delivers results in 43 minutes

    The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
  • Inside the fight against COVID-19 - 28/10/2020 Apogenix_Asunercept_COVID-19_Teaser.png

    A new immunotherapeutic agent for treating severe COVID-19 cases

    Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial - with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Freudenberg Filtration Technologies - 01/10/2020 Kfz-Innenraumfilter von Freudenberg Filtration Technologies scheiden zunächst Partikel und einen Großteil viraler Areosole ab und inaktivieren diese in ihrer letzten, mit Fruchtextrakten imprägnierten bio-funktionalen Schicht

    Coronavirus thwarted: with filters against aerosol spread

    Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.

    https://www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • CeGat GmbH - 06/08/2020 Cegat_Teaser.jpg

    CeGaT: Specific coronavirus antibody test for all

    Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
  • SICOS BW GmbH - 18/06/2020 SICOS BW ermöglicht zusammen mit dem Höchstleistungsrechenzentrum Stuttgart Unternehmen den Zugang zu Data Analytics, Smart Data und Big Data, KI und Virtual-Reality-Technologie.

    High-performance computing and data analytics to combat coronavirus

    In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

    https://www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
  • Vaccine development - 02/06/2020 07777_de.jpg

    CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine?

    All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
  • Trenzyme GmbH - 20/05/2020 Coronavirus im Elektronenmikroskop

    The SARS-CoV spike protein and its receptor

    The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
  • Prime Vector Technologies GmbH - 09/04/2020

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Bioinspired technologies - 03/04/2020 Foto vom Biosensor in Brauntönen; darauf eingezeichnet sind die elektrochemischen Funktionsprinzipien mit Strukturformeln.

    Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests?

    The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Diagnostics-with-molecular-scissors-is-this-also-possible-for-on-site-COVID-19-tests
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine

Page 2 / 2

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search